Lila Levinson, PhD,  Science Writer—

Lila is a Science Writer at BioNews. She completed her PhD in neuroscience at the University of Washington, where she studied how the natural flexibility of the human brain can be used to promote recovery after injury. Previously, she has written about science for The Dallas Morning News and the University of Washington Computational Neuroscience Center. She enjoys exploring the Pacific Northwest and spending time with her cat, Fibonacci.

Articles by Lila Levinson, PhD

Other conditions, processes may mimic CNS involvement in AAV

In ANCA-associated vasculitis (AAV), the involvement of the central nervous system (CNS), that is, the brain and spinal cord, is uncommon, but other factors may mimic CNS involvement, a study reports. These so-called mimickers can include AAV disease processes not related to the CNS, other conditions, and drug-related adverse…

AAV types found to have distinct but overlapping immune pathways

People with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis have elevated levels of certain immune-related proteins in their blood, a new study from Sweden reports. However, different types of AAV involve different immune pathways, depending on the type of antibody involved: proteinase 3, known as PR3, or myeloperoxidase, called MPO.

Blood biomarkers of inflammation may aid AAV assessment: Study

Ratios of different kinds of blood cells, reflecting inflammation and immune activity, may be a cheap and efficient tool to aid in the diagnosis of ANCA-associated vasculitis (AAV), and in predicting disease activity, a new study from China reports. “While not standalone diagnostic tools, these markers offer valuable support…

AAV therapy Tavneos effective in patients with kidney involvement

ANCA-associated vasculitis (AAV) therapy Tavneos (avacopan) is at least as effective as the glucocorticoid prednisone at inducing disease remission, reducing relapse rates, and improving kidney function and quality of life in patients with kidney involvement at treatment start. That’s according to new subgroup analyses from the Phase…